retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial From to Metabolic Health: Why Is a Game-Changer Eli Lilly's retatrutide shows promising

Description

Rivera FB, Cruz LLA, Magalong JV et al (2024) Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials

Optional: 2 oz smoked salmon on top for an extra protein boost (add 12g protein)

M2 macrophage-membrane camouflaged BBR NPs@Mannose enhance targeting and immune evasion while prolonging circulation half-life in an atherosclerosis mouse model [177]

Does the protocol have adverse side effects

Thus, this narrative review explores six commonly used classes of DPP4is, focusing mainly on their features, mechanism of action, advantages, and side effects in comparison with other antidiabetic agents and potential developments using an in silico approach